DBV Technologies SA
PAR:DBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hualan Biological Bacterin Inc
SZSE:301207
|
CN |
|
Harbin Medisan Pharmaceutical Co Ltd
SZSE:002900
|
CN |
|
Wuchan Zhongda Geron Co Ltd
SZSE:002722
|
CN |
|
M
|
Manz AG
XETRA:M5Z
|
DE |
|
BOC Aviation Ltd
HKEX:2588
|
SG |
DBV Technologies SA
Total Assets
DBV Technologies SA
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DBV Technologies SA
PAR:DBV
|
Total Assets
$233.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Valneva SE
PAR:VLA
|
Total Assets
€398.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Assets
€159m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
Inventiva SA
PAR:IVA
|
Total Assets
€179m
|
CAGR 3-Years
16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Total Assets
$324.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Abivax SA
PAR:ABVX
|
Total Assets
€205.2m
|
CAGR 3-Years
40%
|
CAGR 5-Years
24%
|
CAGR 10-Years
10%
|
|
DBV Technologies SA
Glance View
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
See Also
What is DBV Technologies SA's Total Assets?
Total Assets
233.4m
USD
Based on the financial report for Dec 31, 2025, DBV Technologies SA's Total Assets amounts to 233.4m USD.
What is DBV Technologies SA's Total Assets growth rate?
Total Assets CAGR 10Y
-4%
Over the last year, the Total Assets growth was 256%. The average annual Total Assets growth rates for DBV Technologies SA have been -2% over the past three years , -3% over the past five years , and -4% over the past ten years .
